Description
Boldenone Undecylenate (Equipoise, EQ) is a 1-dehydro derivative of testosterone with long undecylenic acid esterification. The substance was originally developed for veterinary medicine (horses) and has never been approved for human use. The recreational community has used EQ for decades nonetheless.
Per study reports Boldenone binds to the androgen receptor with moderate affinity. The substance aromatizes weakly to estradiol - substantially less than testosterone but more than DHT derivatives. This yields a moderate estrogen profile rarely requiring aggressive E2 management in practice.
A characteristic property in recreational research reporting: pronounced increase in appetite and erythropoiesis (red blood cell production). The hematocrit rise under EQ is consistently documented and makes regular blood test controls important.
Pharmacokinetically the undecylenic acid esterification is extremely long - half-life of about 14 days. Steady-state establishes only after 5-6 weeks, making EQ a slow-acting compound. Typical research protocols run 16-20 weeks because the first weeks show barely measurable effects.
Known effects in studies: moderate hematocrit elevation, mild HPG suppression, low estrogen profile, long detection in doping tests (up to 18 months).
Boldenone is on the WADA banned list.
You can order Boldenone Undecylenate as an oily injection solution in 10-pack at 200mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Boldenone Undecylenate is considered moderately tolerated compared to more aggressive anabolics - the effects described in the literature are slow to set in and manageable, but it is no risk-free compound.
Documented in studies and the application literature:
- Erythropoiesis: EQ pronouncedly increases red blood cell production. The hematocrit rise is consistently documented and can lead to polycythemia with elevated thrombosis risk.
- Weak aromatization: Boldenone aromatizes weakly to estradiol - less than testosterone, more than DHT derivatives. The estrogen profile stays moderate, aggressive E2 management is rarely needed.
- Suppression of endogenous production: EQ mildly suppresses the HPG axis. Reduced endogenous testosterone production is documented, a test base is customary in research practice.
- Cardiovascular: the literature describes unfavorable shifts in the lipid profile and cardiac effects with long-term use. Appetite increase is another consistently reported effect.
Baseline bloodwork before, during and after a research protocol is strongly advised, particularly hematocrit monitoring. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Effects of the anabolic steroid, boldenone undecylenate, on certain reproductive parameters in bulls - Theriogenology 1991: documents reproductive effects of boldenone undecylenate in a bull model.
- Screening, confirmation and quantification of boldenone sulfate in equine urine after administration of boldenone undecylenate (Equipoise) - Journal of Chromatography B 1988: detection pharmacokinetics of the main Equipoise metabolites in equine urine.
- Criteria to distinguish between natural situations and illegal use of boldenone, boldenone esters and boldione in cattle - Steroids 2006: doping detection and endogenous-vs-exogenous discrimination.
- Histopathological Effects of Boldenone in Cattle - Journal of Veterinary Medicine Series A 2004: histopathological findings after boldenone administration in cattle.
- A review of current chemistry, pharmacology, and regulation of endogenous anabolic steroids testosterone, boldenone, and nandrolone in horses - Journal of Veterinary Pharmacology and Therapeutics 2023: current review on pharmacology and regulation of boldenone in horses.
